Anixa Biosciences CEO to discuss positive breast cancer vaccine and ovarian cancer therapy data on Bloomberg TV.

Anixa Biosciences announced that CEO Dr. Amit Kumar will appear on Bloomberg TV to discuss the company's progress, including a breast cancer vaccine that met primary endpoints with immune responses in 74% of Phase 1 trial participants, and positive survival data from its ovarian cancer CAR-T therapy, lira-cel, in an ongoing Phase 1 trial. The company partners with leading research institutions like Cleveland Clinic and Moffitt Cancer Center to develop innovative cancer treatments. This media exposure highlights Anixa's advancements and upcoming catalysts in cancer immunotherapy development.